Cenduit announces strategic business alliance with invivodata

Cenduit, LLC, and invivodata, inc., today announce a strategic business alliance to further improve clinical trial efficiencies by adding the scientific and operational benefits of invivodata’s electronic Patient Reported Outcomes (ePRO) solutions to the proven efficiencies of Cenduit‘s Interactive Response Technology solution (IRT).

“By partnering with Cenduit, I am confident that we will deliver a truly unique solution to sponsors by extending and driving efficiencies in the real-world use of clinical solutions”

Cenduit’s IRT solution is instrumental in collecting, analyzing, and managing clinical trial data. Cenduit’s pharmaceutical, clinical research, and biotechnology customers rely on IRT solutions to effectively manage randomization and drug supply management of their clinical studies. invivodata’s ePRO solutions address the poor reliability of paper diaries by ensuring data is captured according to study protocol, resulting in enhanced speed, efficiency, and accuracy of PRO data in clinical trials.

Through this non-exclusive strategic alliance Cenduit can provide a fully integrated ePRO solution allowing key ePRO data to be fully integrated with Cenduit’s IRT offering. The combination of Cenduit’s IRT platform combined with invivodata’s EPX™ ePRO management system, supported by invivodata’s global consulting, ePRO site readiness and data management services, will provide sponsors with a uniquely integrated and streamlined approach to collecting the highest quality ePRO data in clinical trials.

“Our partner selection criteria were simple: align with the best ePRO solution provider in the global marketplace. invivodata is a proven, progressive, nimble organization with the leadership and vision to ensure healthy growth and superior delivery and customer support. The invivodata team clearly demonstrates the business disciplines and results that we value,” stated Dr. Jogin Desai, chief executive officer, Cenduit, LLC.

“By partnering with Cenduit, I am confident that we will deliver a truly unique solution to sponsors by extending and driving efficiencies in the real-world use of clinical solutions,” cites Doug Engfer, chief executive officer, invivodata, inc. “Cenduit has a compelling, forward-looking vision for creating and realizing clinical-trial efficiencies, and our organizations and solutions are aligned to deliver a powerful business-oriented approach to conducting more efficient and effective clinical research.”